Published in Cancer Weekly, May 17th, 2005
The phase 3 study, coined the ETHECC trial (Evaluation of Thymitaq in Unresectable Hepatocellular Carcinoma), is comparing survival in a randomized trial of patients with inoperable primary liver cancer treated with Thymitaq, an investigational product, to patients treated with doxorubicin.
There is no treatment approved by the United States Food and Drug Administration (FDA) or the European Agency for the Evaluation of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.